BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37370730)

  • 1. 'Earlier than Early' Detection of Breast Cancer in Israeli
    Anaby D; Shavin D; Zimmerman-Moreno G; Nissan N; Friedman E; Sklair-Levy M
    Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pregnancy Associated Breast Cancer Among Israeli BRCA1/BRCA2 Carriers in a High-Risk Clinic.
    Faermann R; Friedman E; Kaidar-Person O; Brodsky M; Neiman OH; Shalmon A; Gotlieb M; Yagil Y; Samocha D; Feldman DM; Weidenfeld J; Sklair-Levy M
    Acad Radiol; 2023 Feb; 30(2):248-254. PubMed ID: 35527100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
    Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S
    Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
    Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
    Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic and clinical characterization of BRCA-associated hereditary breast and ovarian cancer in Navarra (Spain).
    Ruiz de Sabando A; Urrutia Lafuente E; García-Amigot F; Alonso Sánchez A; Morales Garofalo L; Moreno S; Ardanaz E; Ramos-Arroyo MA
    BMC Cancer; 2019 Nov; 19(1):1145. PubMed ID: 31771539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subsequent breast and high grade serous carcinomas after risk-reducing salpingo-oophorectomy in BRCA mutation carriers and patients with history of breast cancer.
    Straub MM; Podoll MB; David SN; Wiesner GL; Desouki MM
    Ann Diagn Pathol; 2018 Oct; 36():28-30. PubMed ID: 30055521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polygenic risk scores indicate extreme ages at onset of breast cancer in female BRCA1/2 pathogenic variant carriers.
    Borde J; Laitman Y; Blümcke B; Niederacher D; Weber-Lassalle K; Sutter C; Rump A; Arnold N; Wang-Gohrke S; Horváth J; Gehrig A; Schmidt G; Dutrannoy V; Ramser J; Hentschel J; Meindl A; Schroeder C; Wappenschmidt B; Engel C; Kuchenbaecker K; Schmutzler RK; Friedman E; Hahnen E; Ernst C
    BMC Cancer; 2022 Jun; 22(1):706. PubMed ID: 35761208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast cancer surveillance following ovarian cancer in BRCA mutation carriers.
    John CS; Fong A; Alban R; Gillen J; Moore KM; Walsh CS; Li AJ; Rimel BJ; Amersi F; Cass I
    Gynecol Oncol; 2022 Jan; 164(1):202-207. PubMed ID: 34862065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers.
    Grindedal EM; Heramb C; Karsrud I; Ariansen SL; Mæhle L; Undlien DE; Norum J; Schlichting E
    BMC Cancer; 2017 Jun; 17(1):438. PubMed ID: 28637432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
    Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
    Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical breast exam contribution to breast cancer diagnosis in BRCA mutation carriers vs. average to intermediate risk women.
    Menes TS; Zippel D; Sklair-Levy M; Friedman E; Bernstein-Molho R; Faermann R; Madorsky Feldman D
    Breast Cancer Res Treat; 2024 May; ():. PubMed ID: 38797791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast Cancer Surveillance Following Ovarian Cancer in BRCA Mutation Carriers.
    Fong A; Cass I; John C; Gillen J; Moore KM; Gangi A; Walsh C; Li AJ; Rimel BJ; Karlan BY; Amersi F
    Am Surg; 2020 Oct; 86(10):1243-1247. PubMed ID: 33106023
    [No Abstract]   [Full Text] [Related]  

  • 13. Prevalence of specific and recurrent/founder pathogenic variants in BRCA genes in breast and ovarian cancer in North Africa.
    ElBiad O; Laraqui A; El Boukhrissi F; Mounjid C; Lamsisi M; Bajjou T; Elannaz H; Lahlou AI; Kouach J; Benchekroune K; Oukabli M; Chahdi H; Ennaji MM; Tanz R; Sbitti Y; Ichou M; Ennibi K; Badaoui B; Sekhsokh Y
    BMC Cancer; 2022 Feb; 22(1):208. PubMed ID: 35216584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiological and clinicopathological characteristics of BRCA-positive and BRCA-negative breast cancer patients in Greece.
    Triantafyllidou O; Vlachos IS; Apostolou P; Konstantopoulou I; Grivas A; Panopoulos C; Dimitrakakis C; Kassanos D; Loghis C; Bramis I; Vlahos N; Yannoukakos D; Fostira F
    J BUON; 2015; 20(4):978-84. PubMed ID: 26416046
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Incorvaia L; Fanale D; Bono M; Calò V; Fiorino A; Brando C; Corsini LR; Cutaia S; Cancelliere D; Pivetti A; Filorizzo C; La Mantia M; Barraco N; Cusenza S; Badalamenti G; Russo A; Bazan V
    Ther Adv Med Oncol; 2020; 12():1758835920975326. PubMed ID: 33403015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reproductive factors as risk modifiers of breast cancer in
    Park B; Hopper JL; Win AK; Dowty JG; Sung HK; Ahn C; Kim SW; Lee MH; Lee J; Lee JW; Kang E; Yu JH; Kim KS; Moon BI; Han W; Noh DY; Park SK;
    Oncotarget; 2017 Nov; 8(60):102110-102118. PubMed ID: 29254229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic, clinic and histopathologic characterization of BRCA-associated hereditary breast and ovarian cancer in southwestern Finland.
    Pallonen TA; Lempiäinen SMM; Joutsiniemi TK; Aaltonen RI; Pohjola PE; Kankuri-Tammilehto MK
    Sci Rep; 2022 Apr; 12(1):6704. PubMed ID: 35469032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?
    McGee J; Giannakeas V; Karlan B; Lubinski J; Gronwald J; Rosen B; McLaughlin J; Risch H; Sun P; Foulkes WD; Neuhausen SL; Kotsopoulos J; Narod SA;
    Gynecol Oncol; 2017 May; 145(2):346-351. PubMed ID: 28314588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast cancer surveillance for BRCA1/2 mutation carriers - is "early detection" early enough?
    Bernstein-Molho R; Kaufman B; Ben David MA; Sklair-Levy M; Feldman DM; Zippel D; Laitman Y; Friedman E
    Breast; 2020 Feb; 49():81-86. PubMed ID: 31760168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast cancer risk in
    Nañez A; Stram DA; Bethan Powell C; Garcia C
    Gynecol Oncol Rep; 2022 Feb; 39():100899. PubMed ID: 34917730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.